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The process of scar formation and wound healing (►Fig. 1)
represents a variable and unpredictable course of the natural
healing process. Although scar formation is crucial to the
normal healing mechanism, facial scars can often become
unsightly and cause patients to develop psychosocial insecu-
rities given the degree of cosmetic deformity. Aside from the
cosmetic deformation, scars on the face can have functional
consequences as well depending on the degree and vector of
contracture. The challenges and lack of unified treatment
modalities have led to the evolution of multiple revision
techniques, both surgical and nonsurgical. Although the
literature evaluating efficacy of these modalities is broad
and there exist many inconsistencies in outcomes, it is
important for the facial plastic surgeon to understand the
different options available for treatment.
Prior to undertaking any treatment, a full examination of
the scar and a thorough understanding of the patient’s dis-
satisfactionare important in formulatingapatient-centric goal
for improvement. As no single approach is applicable to all
patients, it is paramount to discuss expectations with the
patient, asmany times complete resolution of thescarmaynot
bepossible and reorientation or camouflaging techniquesmay
be feasible alternatives. A majority of reviews in the literature
have focused on surgical or nonsurgical options for scar
management without providing the reader with a single
source for an overview of all options. In this article, we seek
not to provide an in-depth discussion of every singlemodality
for scar revision, but to provide the reader with a reference list
that can then be explored further at the surgeon’s discretion.
Options for Scar Revision
Topical and Intralesional Options
Topical creams are often the first-line treatment for scars due
to their low cost, favorable side-effect profile, and ease of
availability. Similarly, intralesional pharmacotherapies are
commonly employed in the early treatment of scars. Topical
creams such as vitamin E, antibiotic ointments, sunscreens,
and petroleum jellies are often most effective in the acute/
immediate postoperative setting. These therapies work to
optimize healing and minimize visible scarring. Nevertheless,
thereare someointment/creamsthat areknowntobeeffective
in the treatment of certain scars. Intralesional therapies
involve injections into the targeted scars and usually multiple
injections over an extended timeperiod. Oftenvarious intrale-
sional therapiesmay be combined to improve the likelihood of
successful conservative therapies.
Silicone Products
Silicone gels and sheeting have been shown to be effective in
the treatment of cutaneous scars. Silicone-based products
have become amainstay in clinical practice and are known to
reduce hypertrophy through sealing and hydrating dense
scar tissue.1 In fact, silicone products are regarded as one of
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the few options for scar therapy with sufficient backing by
scientific evidence and considered by some to be the gold
standard for noninvasive scar management techniques.2,3
Silicone sheeting typically consists of a sheet made from
silicone gel reinforced by a silicone and/or polytetrafluor-
oethylene membrane.4
Themajority of studies have looked at silicone gel sheeting;
however, studies evaluating silicone-based gels have shown
that these newer gels have efficacy that is comparable to
sheeting, especially for facial scars.1,5,6Siliconesheeting,which
can be used to prevent or treat existing scars, can be used as
long as the patient continues to obtain benefit, as the side
effects are negligible.3 It is important to note that thismodality
should not be used on openwounds. A meta-analysis demon-
strated that silicone sheeting significantly reduced the forma-
tionofhypertrophic scars inhigh-riskpatients.7Silicone-based
products may be used in conjunction with intralesional injec-
tions of steroids or 5-fluorouracil (5-FU).
Imiquimod
Imiquimod is an immune systemmodulator that functions by
activating toll-like receptors(TLRs) and subsequently stimulat-
ing the production of cytokines and antigen presentation.
Ultimately, this results in an increased immune response in
treated tissues.Oftenused in the treatmentofanogenitalwarts
and as a topical therapy for basal cell carcinomas, imiquimod is
also frequentlyused in the treatmentofhypertrophic scarsand
keloids.8,9 It can be used alone; however, it is most commonly
used after surgical or shave excision of the lesion, with daily
application of 5% imiquimod cream to the scar. Most studies
report frequent recurrences of keloids despite imiquimod.
However, there is evidence to suggest that keloids of the pinna
are particularly responsive to imiquimod.8,9
Corticosteroids
Corticosteroids have been a mainstay in the treatment of
hypertrophic scars and keloids for decades. The vast prepon-
derance of evidence for steroids has been with intralesional
therapy. However, ointments/creams can be used as the first-
line treatment prior to injections. Corticosteroids have been
shown to reduce fibroblast proliferation and collagen synth-
esis. Steroids also suppress the production of inflammatory
cytokines and alter gene expression in keratinocytes. This
includes suppression of transforming growth factor-beta
(TGF-β),whichhasbeen linkedto thedevelopmentofkeloids.10
Intralesional corticosteroids remain a prime for keloids
and second line for hypertrophic scars.5,11 Treatment usually
consists of monthly intralesional injections with regular
follow-up and reassessment to monitor the treatments. It
is also important to note that steroid therapy can be paired
with other treatments. Corticosteroids have also been shown
to be effective as an adjunctive agent to other therapies
including cryotherapy or 5-FU.6,12
Bleomycin
Bleomycin is a cytotoxic polypeptide that induces DNA strand
breaks. Bleomycin functions by inhibiting the proliferation of
fibroblasts and other inflammatory cells. Bleomycin has been
shown to be effective in the treatment of cutaneous scars and
keloids. Intralesional bleomycin injections have been shown to
reduce pain/pruritus and result in scar flattening. Bleomycin
can be combinedwith a local anesthetic to improve bleomycin
uptake into cells. Bleomycin treatments usually involve single
injections;however, the treatmentcanberepeated3 to4weeks
after the initial injection. It is alsoworth noting that bleomycin
may be used alone or in conjunction with intralesional
triamcinolone.5,6,12,13
5-Fluorouracil
5-fluorouracil is a pyrimidine analog that is cytotoxic due to its
inhibitionof thymidylatesynthase.When injected into scarsor
applied topically, it inhibits the proliferation of fibroblasts.
Clinically, it has been successfully used in the treatment of
scars for decades andwith excellent response rates.5 5-FU can
be injected alone as monotherapy, or it can be combined with
corticosteroids (usually triamcinolone). In a recent review of
the literature, Shah et al report that keloid response rates with
5-FU alone range from 45 to 78%. However, when combined
with triamcinolone, response rates improved to 96%.14 5-FU
can also be used in conjunctionwith laser therapies; however,
5-FU alone may achieve results comparable to those achieved
in conjunction with the laser.
Mitomycin C
Mitomycin C is another cytotoxic agent that has been used to
treat hypertrophic scars and keloids. Mitomycin C has been
Fig. 1 Stages of wound healing. (A) Inflammatory phase. (B) Proliferative phase. (C) Remodeling phase.
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showntobeeffectivewhenusedtopicallyafter surgical excision
ofkeloids;however, its efficacyasa topical agentonunoperated
tissue is yet to be demonstrated in the literature.5
Dermabrasion
Dermabrasion is a skin resurfacing technique that was first
described in the 1930s. It was initially used for tattoo
removal, but it has since proven itself effective in treating
a variety of dermatologic conditions. Dermabrasion relies on
a rotating abrasive tip (wire or diamond tip) to cause a
controlled ablation of superficial skin layers. The goal is to
remove layers until the level of the papillary-reticular dermal
junction. Dermabrasion relies on proper technique
to minimize thermal injury and to ensure appropriate depth
of abrasion. The appropriate depth can be identified by
pinpoint bleeding that marks the papillary dermis layer
followed by the parallel collagen segment that marks the
correct depth of abrasion.15,16
Subsequent healing is driven by the surrounding epithe-
lium and results in a smoother scar without excess thickness.
Dermabrasion has been shown to be effective in the treat-
ment of a variety of scars including acne, surgical scars,
actinic keratosis, rhinophyma, and facial rhytids.16–19 Ulti-
mately, dermabrasion represents a simple and cost-effective
option for the treatment of a variety of scars.
Laser Therapies
Various lasers have been used in a multitude of different
manners to treat scars. Historically, lasers have been used
either as ablative therapy or nonablative therapy. Photody-
namic therapy (PDT) represents a newer technology that
utilizes lasers for the treatment of a variety of skin conditions.
Ablative Lasers
Ablative lasers utilize the laser to ablate skin layers to the depth
of the papillary dermis. CO2 lasers were first described for skin
resurfacing in 1985. Subsequently, the erbium-doped yttrium
aluminium garnet (Er:YAG) laser was introduced and today
both are used for laser ablation. The CO2 laser creates a zone of
thermal injury 200 µm in depth, whereas the pulsed Er:YAG
laser creates a zone of injury of approximately 50 µm. As such,
the Er:YAG laser produces less thermal injury and has a lower
depth of penetration. Hence, the Er:YAG laser may be titrated
better than the CO2 laser. Both lasers are effective and can be
used in the treatment of scars, skin rejuvenation, and other skin
conditions including rhinophyma and the cutaneous manifes-
tations of tuberous sclerosis.20
Fractional ablation is a newer technique that was first
described in 2004 by Manstein et al as fractional photolysis.21
In fractional ablation, the laser is used to ablate tissue in the
target field in a pixelated fashion. This leaves behind islands of
healthy tissue that lead to faster healing and with fewer side
effects. Tidwell et al recently published a double-blinded split
scar study that showed that fractionated Er:YAG laser was
superior to the fully ablative laser for scar revision.22
Ablative lasers do have their side effects and postproce-
dure erythema can last for weeks. Patients with darker skin
are more likely to have pigmentary changes, ranging from
postinflammatory hyperpigmentation to delayed hypopig-
mentation. Patients may also experience acneiform erup-
tions andworsening of scar from ablative laser treatments.23
Fractionated laser treatments represent a newer technique
that may ameliorate some of these adverse effects.
Nonablative Lasers
Nonablative lasers represent a treatment modality for less
severe lesions in patients who are seeking milder results and
faster recoveries. Nonablative lasers aim to protect the epi-
dermis and selectively destroy dermal tissues. Often it is the
microvasculature within the dermis that is targeted by these
lasers. Cooling of the epidermis with cryospray or air cooling
can be used to protect the dermis from the effects of the
laser.20,23 Nonablative lasers use different gain media than
lasers used in ablative laser treatments. The most commonly
used nonablative lasers are the neodymium-doped yttrium
aluminium garnet laser, pulsed potassium titanyl phosphate
lasers, or diode lasers. These treatments are effective inmild to
moderatewrinkles and similar lesions. However, these are not
typically used for scar revision.20,23
Photodynamic Therapy
Photodynamic therapy utilizes an optically active drug that
is delivered to targeted tissues and then activated by light.
The first and most commonly used photosensitive agent is
5-aminolevulinic acid. Methyl aminolevulinic acid is another
photoactive agent. Upon activationwith light, reactive oxygen
species are formed in the targeted tissue resulting in tissue
ablation. This treatment methodology has been explored in a
variety of medical/surgical disciplines and remains an active
area of research. The literature contains reports of PDT being
used to treat a variety of dermatologic conditions ranging from
vascular malformations, to cancers, to scars. Some basic
science work has been done showing the efficacy of PDT in
killing keloidfibroblasts.24Recently, therehavebeen reports in
the literature of PDTbeing used in the treatment of keloids and
surgical scars.25 Most treatment protocols described in the
literature involve weekly PDT sessions.
PDT represents a promising treatment modality for a
variety of conditions. Treatment protocols will likely con-
tinue to evolve as more research is conducted on the efficacy
of PDT and into novel photosensitizing agents.26,27
Surgical Management
Surgical management of scars represents an option for scar
revision that can be undertaken primarily or following failure
of conservative measures depending on the patient’s motiva-
tionandgoals. As scar revision oftentimes entails the “trading”
ofonescar foranother,or simplythereorientationofa scar into
a less conspicuous location, precision and planning are of
utmost important. As patients have differing propensities to
form scars, handling soft tissue in an atraumatic fashionwhile
being aware of facial subunits and relaxed skin tension lines is
crucial for a successful outcome.28 Multiple options exist for
planning scar revision, with varying levels of complexity.
Selected techniques along with descriptions and illustrations
where appropriate are described below.
Facial Plastic Surgery Vol. 33 No. 6/2017
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Ellipse
The simplest method of revising a scar is to excise an ellipse of
tissue around it followed by primary closure of the wound
edges. Estimating approximately 30-degree angles at the
corners of the ellipse, the scar can be excised while placing
the new incision line either within or parallel to a relaxed skin
tension line.28 It is important to note that a multilevel closure
with careful attention to redundant tissue at the edges is
crucial to a cosmetically favorable outcome.
Geometric Broken Line Closure
For longer scars, the geometric broken line technique can be
useful in camouflaging the scar as it creates an irregular
appearance. Created with irregular and asymmetric geo-
metric shapes, the scar is less perceptible to the human
eye following closure (►Fig. 2).
M-Plasty
M-plasty is a technique of scar revision that is based on
modifying an elliptical excision. In certain locations, healthy
tissue may not want to be sacrificed and as such, the
M-plasty saves more native tissue while maintaining similar
angles as utilized in an ellipse technique (►Fig. 3).
W-Plasty
Another useful technique in camouflaging a scar that may
not be in a favorable location, similar to the geometric
broken line design, the W-plasty also makes a scar more
irregular and hence, less perceptible to the eye. The inci-
sion is designed by making consecutive “W” designs on
both sides of the scar, followed by excision and reapprox-
imation to give a jagged, saw-toothed appearance to the
scar (►Fig. 4).
Fig. 2 Geometric broken line closure. (A) Initial scar with incision
marking. (B) Final closure following excision of previous scar.
Fig. 3 M-plasty. (A) Initial defect with planned M-plasty incision. (B) Excised skin with vectors of movement. (C) Final closure of M-plasty.
Fig. 4 W-plasty. (A) Initial scar with incision marked in irregular
fashion. (B) Final closure following excision of previous scar.
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Z-Plasty
Z-plasty is a versatile technique in scar revision used to
lengthen and reorient the angles of a scar. The initial scar is
used as the central portion of the “Z” while obliquely
oriented limbs are made on either side to rotate and change
scar appearance. Typically, 30-degree angles lengthen a scar
by 25%, 45-degree angles lengthen by 50%, and 60-degree
angles lengthen by 75% (►Fig. 5).
Radiation Therapy
Radiation therapy for scar management, particularly keloids,
has been well described in the literature; however, the
application of this therapy is highly dependent on institu-
tions and practice patterns. It is the senior author’s (Y.D.)
belief that in some circumstances, single-dose same day
postoperative external beam radiation for recurrent keloids
can be a useful treatment adjunct. Song et al have reported
that their experience of delivering a single-fraction electron
beam radiation dose of 10 Gy immediately postoperatively
led to no recurrence and no adverse side effects.29 Another
2016 studied found that the delivery of 18 Gy divided into
three fractions within the first 36 hours postoperatively
resulted in a 94% local control rate of intractable keloids,
with no procedure-related complications.30 A recent meta-
analysis in the plastic surgery literature analyzing 9,048
keloids treated with postoperative radiotherapy found that
there was indeed a lower recurrence rate in patients treated
postoperatively compared with those treated with radio-
therapy alone.Moreover, they reported the lower recurrence
rates with brachytherapy compared with electron beam and
X-ray.31 It appears that the use of postoperative radiation
therapy is immensely helpful; however, the modality and
fractionation regimen are yet to be agreed upon.
Conclusion
Facial scars can result in anunacceptable cosmetic appearance.
Multiple options for the management of scars are available,
including topic medications, intralesional injections, laser
therapy, dermabrasion, photodynamic treatment, and surgical
management. Although no single modality is superior, it is
important for the practitioner to recognize the multifaceted
approach to scar management keeping in mind the patient’s
goals and preferences. Management of expectations and clear
communication can allow the patient to participate in their
care and lead to greater satisfaction with posttreatment
outcomes.
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